Get the Stockscreener App
135.75
0.56%
0.76
After Hours:
135.75
Axsome Therapeutics Inc stock is traded at $135.75, with a volume of 1.24M.
It is up +0.56% in the last 24 hours and up +12.84% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$134.99
Open:
$123.9
24h Volume:
1.24M
Relative Volume:
2.32
Market Cap:
$6.77B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-20.79
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
+0.79%
1M Performance:
+12.84%
6M Performance:
+20.98%
1Y Performance:
+52.80%
1-Day Range:
$123.50
$137.85
1-Week Range:
$123.50
$137.85
52-Week Range:
$75.56
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
135.75 | 6.74B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Initiated | Oppenheimer | Outperform |
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Axsome: Q3 Earnings Snapshot - CTPost
Axsome Therapeutics Q3 2025 slides: Strong revenue growth amid pipeline expansion - Investing.com
Axsome Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Transcript : Axsome Therapeutics, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Earnings call transcript: Axsome Therapeutics Q3 2025 reveals revenue beat, stock dips - Investing.com
Is Axsome Therapeutics Inc. forming a reversal pattern2025 Market Outlook & Reliable Breakout Forecasts - newser.com
Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Axsome Therapeutics Saw Sales Jump But Losses Remain - Finimize
Market reaction to Axsome Therapeutics Inc.’s recent newsWeekly Investment Recap & Fast Gain Stock Trading Tips - newser.com
Axsome Q3 2025 Financial Results: Revenue Beats, Loss WidensNews and Statistics - IndexBox
Axsome Therapeutics Reports 63% Revenue Growth in Q3 2025 - TipRanks
Earnings Flash (AXSM) Axsome Therapeutics, Inc. Reports Q3 Revenue $171.0M, vs. FactSet Est of $163.0M - MarketScreener
Axsome Therapeutics Inc. stock momentum explainedJuly 2025 Snapshot & Free High Accuracy Swing Entry Alerts - newser.com
Axsome Therapeutics Q3 net product revenue jumps 63% - MarketScreener
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Bluefield Daily Telegraph
How Axsome Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Setups & AI Enhanced Trading Signals - newser.com
Axsome Therapeutics Inc. recovery potential after sell offJuly 2025 Opening Moves & Reliable Price Action Trade Plans - newser.com
Will Axsome Therapeutics Inc. stock sustain high P E ratios2025 Growth vs Value & Daily Stock Trend Reports - newser.com
Will Axsome Therapeutics Inc. stock go up soonBuy Signal & Free Daily Entry Point Trade Alerts - newser.com
Axsome Therapeutics Inc. stock volume spike explained2025 Dividend Review & Verified Entry Point Signals - newser.com
Historical volatility pattern of Axsome Therapeutics Inc. visualized2025 Key Lessons & Daily Technical Forecast Reports - newser.com
How Axsome Therapeutics Inc. (19X) stock reacts to Fed tighteningJuly 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - newser.com
Can machine learning forecast Axsome Therapeutics Inc. recoveryWeekly Investment Summary & Accurate Buy Signal Alerts - newser.com
Can Axsome Therapeutics Inc. stock continue upward trendJuly 2025 PreEarnings & Verified Swing Trading Watchlists - newser.com
What Wall Street predicts for Axsome Therapeutics Inc. stock pricePortfolio Profit Report & Short-Term Trading Opportunity Alerts - newser.com
Is a relief rally coming for Axsome Therapeutics Inc. holders2025 Fundamental Recap & AI Powered Trade Plan Recommendations - newser.com
How Axsome Therapeutics Inc. (19X) stock moves in volatile trading sessionsTrade Performance Summary & Long-Term Capital Growth Strategies - newser.com
Is Axsome Therapeutics Inc. stock a buy on dips2025 Key Lessons & Weekly Watchlist for Hot Stocks - newser.com
Why hedge funds are buying Axsome Therapeutics Inc. stockWeekly Stock Report & Daily Volume Surge Trade Alerts - newser.com
State of New Jersey Common Pension Fund D Grows Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
How Axsome Therapeutics Inc. stock compares to market leadersQuarterly Profit Summary & Weekly High Conviction Ideas - newser.com
Is Axsome Therapeutics Inc. stock gaining market shareMarket Trend Summary & Consistent Income Trade Ideas - newser.com
Is Axsome Therapeutics Inc. stock attractive after correctionStock Surge & Risk Adjusted Buy/Sell Alerts - newser.com
How Axsome Therapeutics Inc. stock performs in rate cut cyclesMarket Trend Summary & Daily Profit Maximizing Trade Tips - newser.com
Is Axsome Therapeutics Set for More Gains After Promising Clinical Trial News in 2025? - Sahm
Q1 EPS Forecast for Axsome Therapeutics Boosted by Analyst - MarketBeat
How rising interest rates impact Axsome Therapeutics Inc. stockRisk Management & Smart Swing Trading Techniques - newser.com
Emerald Mutual Fund Advisers Trust Takes $6.67 Million Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
What candlestick patterns are forming on Axsome Therapeutics Inc.Exit Point & Weekly Momentum Picks - newser.com
Has Axsome Therapeutics Inc. formed a bullish divergenceWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - newser.com
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):